[go: up one dir, main page]

DE10299023I2 - Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff - Google Patents

Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff

Info

Publication number
DE10299023I2
DE10299023I2 DE10299023C DE10299023C DE10299023I2 DE 10299023 I2 DE10299023 I2 DE 10299023I2 DE 10299023 C DE10299023 C DE 10299023C DE 10299023 C DE10299023 C DE 10299023C DE 10299023 I2 DE10299023 I2 DE 10299023I2
Authority
DE
Germany
Prior art keywords
antineoplastic
potentiating
effect
active
antineoplastic effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE10299023C
Other languages
English (en)
Other versions
DE10299023I1 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAHIO PHARMACEUTICAL CO Ltd
Original Assignee
TAHIO PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17034249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10299023(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by TAHIO PHARMACEUTICAL CO Ltd filed Critical TAHIO PHARMACEUTICAL CO Ltd
Application granted granted Critical
Publication of DE10299023I1 publication Critical patent/DE10299023I1/de
Publication of DE10299023I2 publication Critical patent/DE10299023I2/de
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE10299023C 1990-09-07 1991-09-05 Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff Active DE10299023I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23871990 1990-09-07
PCT/JP1991/001187 WO1992004028A1 (en) 1990-09-07 1991-09-05 Antineoplastic effect potentiator and antineoplastic agent

Publications (2)

Publication Number Publication Date
DE10299023I1 DE10299023I1 (de) 2003-06-05
DE10299023I2 true DE10299023I2 (de) 2010-05-06

Family

ID=17034249

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10299023C Active DE10299023I2 (de) 1990-09-07 1991-09-05 Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
DE69121551T Expired - Lifetime DE69121551T2 (de) 1990-09-07 1991-09-05 Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69121551T Expired - Lifetime DE69121551T2 (de) 1990-09-07 1991-09-05 Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff

Country Status (14)

Country Link
EP (1) EP0500953B1 (de)
JP (1) JP2557303B2 (de)
KR (1) KR0146952B1 (de)
AT (1) ATE141506T1 (de)
AU (1) AU644684B2 (de)
CA (1) CA2071819A1 (de)
DE (2) DE10299023I2 (de)
DK (1) DK0500953T3 (de)
ES (1) ES2091941T3 (de)
GR (1) GR3021003T3 (de)
HU (1) HU211739A9 (de)
LU (1) LU90791I2 (de)
NL (1) NL300041I2 (de)
WO (1) WO1992004028A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05310573A (ja) * 1992-05-01 1993-11-22 Dotsuto:Kk リウマチ治療薬
US5643191A (en) * 1995-01-26 1997-07-01 Sorin Biomedical Inc. Cardioplegia delivery system and method for converting from warm cardioplegia to cold cardioplegia
US5702358A (en) * 1995-02-23 1997-12-30 Sorin Biomedical Inc. Cardioplegia delivery apparatus and method of use
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US6538001B1 (en) * 1998-10-12 2003-03-25 Nikolai Borisovich Leonidov Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect
DE602004016636D1 (de) 2003-03-14 2008-10-30 Taiho Pharmaceutical Co Ltd Eine die antitumorwirkung verstärkende verbindung und antitumormittel
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
AU2008356312B2 (en) 2008-05-12 2015-04-09 Shizuoka Prefecture Antitumor agent, kit, and method for treating cancer
KR102258514B1 (ko) * 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5953885B2 (ja) * 1978-02-10 1984-12-27 大鵬薬品工業株式会社 抗腫瘍剤組成物
GB2016921B (en) * 1978-03-27 1982-08-18 Taiho Pharmaceutical Co Ltd Anti cancer compositions containing uracil derivatives
JPS5780319A (en) * 1980-11-06 1982-05-19 Taiho Yakuhin Kogyo Kk Anti-tumor agent having reduced toxicity

Also Published As

Publication number Publication date
NL300041I2 (nl) 2002-02-01
KR0146952B1 (ko) 1998-08-17
DK0500953T3 (da) 1997-01-06
AU644684B2 (en) 1993-12-16
ES2091941T3 (es) 1996-11-16
GR3021003T3 (en) 1996-12-31
KR927002224A (ko) 1992-09-03
DE69121551T2 (de) 1997-01-02
EP0500953A1 (de) 1992-09-02
NL300041I1 (nl) 2001-06-01
HU211739A9 (en) 1995-12-28
ATE141506T1 (de) 1996-09-15
AU8447991A (en) 1992-03-30
EP0500953B1 (de) 1996-08-21
DE10299023I1 (de) 2003-06-05
LU90791I2 (fr) 2001-10-08
DE69121551D1 (de) 1996-09-26
WO1992004028A1 (en) 1992-03-19
EP0500953A4 (en) 1993-04-21
JP2557303B2 (ja) 1996-11-27
CA2071819A1 (en) 1992-03-08

Similar Documents

Publication Publication Date Title
NL970006I1 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
DE69318031D1 (de) Ematiomerenreine beta-d-dioxolane nucleoside mit selektiver antihepatitis b-virus wirkung
DE59102210D1 (de) Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus.
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
DE69322251D1 (de) Medizinische zusammensetzung
TNSN90021A1 (fr) Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales
DE10299023I2 (de) Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
WO1990014831A3 (en) 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
BG100599A (en) Antiviral form and therapeutical method
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
MY104521A (en) Treatment of depression.
DE69019404D1 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
DE3867251D1 (de) Medikamente fuer die behandlung von rheumatoider arthritis.
ATE210445T1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 7 infektionen
DK0814813T3 (da) Anvendelse af penciclovir til behandling af human herpesvirus-8
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
KR890007737A (ko) 진토작용을 하는 약제
DE69228945D1 (de) Pharmazeutische pentapeptid-zusammensetzung und ihre verwendung
ES2062752T3 (es) Preparado de una sal de oxipurinol en forma oral para el tratamiento de hiperuricemia.
DE69429538D1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 6 infektionen